ReciBioPharm, the advanced and emerging therapies business unit within Recipharm, Acuitas Therapeutics report that they are taking their partnership to the next level. The companies say they ready to perform technology transfers and CGMP manufacturing for customers licensing Acuitas’ lipid nanoparticle (LNP) formulations for mRNA-based therapeutics and vaccines.

ReciBioPharm first partnered with Acuitas Therapeutics in May of 2022 as Arranta Bio (now part of ReciBioPharm) and has since transferred and manufactured multiple Acuitas LNP formulations for planned clinical trials around the globe. While initial work with Acuitas has been supporting clinical demand, ReciBioPharm will now focus on the progression of advanced therapeutics.

“This collaboration has enabled a number of Acuitas partners to rapidly progress from concept to clinic thanks to Acuitas’ deep process and analytical experience and our flexible development capability and strong CGMP execution,” said Nathaniel Youndt, VP of business strategy and program management at ReciBioPharm. “We look forward to continuing our work together and, with Acuitas’ licensed customer base, to bringing new mRNA-based therapeutics to patients.”

Ongoing work with Acuitas is being performed at ReciBioPharm’s U.S. Center of Excellence for Nucleic Acids–an 80,000 ft2 facility in Watertown, MA, with 10,000 ft2 of process development labs, 5,000 ft2 of analytical labs, and 13 CGMP production suites. ReciBioPharm provides a comprehensive nucleic acid solution under one roof at its Watertown site, producing E. coli plasmid cell banks, CGMP plasmid DNA, multiple types of RNA drug substances, and LNP formulations with sterile fill-finish, according to Youndt.

Previous articleLiquid Biopsy Uses ctDNA to Predict Recurrence of Hodgkin Lymphoma
Next articleBrainoware: Organoid Neural Networks Inspire Brain-AI Hardware